Collegium Pharmaceutical

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent protected DETERx™ formulation platform.
Type
Public
HQ
Cumberland, US
Founded
2002
Size (employees)
46 (est)
Collegium Pharmaceutical was founded in 2002 and is headquartered in Cumberland, US

Key People at Collegium Pharmaceutical

Michael T. Heffernan

Michael T. Heffernan

Co - Founder, President & CEO
Michael Heffernan

Michael Heffernan

Co-Founder, President, CEO
Heow Tan

Heow Tan

Vice President of Technical Operations

Collegium Pharmaceutical Office Locations

Collegium Pharmaceutical has an office in Cumberland
Cumberland, US (HQ)
400 Highland Corporate Drive

Collegium Pharmaceutical Metrics

Collegium Pharmaceutical Financial Metrics

Net income (FY, 2016)

($94.2 m)

EBIT (FY, 2016)

($94.1 m)

Market capitalization (23-May-2017)

$270.4 m

Closing share price (23-May-2017)

$8.4

Cash (31-Dec-2016)

$153.2 m
Collegium Pharmaceutical's current market capitalization is $270.4 m.
FY, 2015FY, 2016

R&D expense

$8 m$14.9 m

General and administrative expense

$18.9 m$80.6 m

Operating expense total

$26.9 m$95.8 m

EBIT

($26.9 m)($94.1 m)

Interest expense

$439 k$94 k

Net Income

($27.3 m)($94.2 m)
FY, 2015FY, 2016

Cash

$95.7 m$153.2 m

Accounts Receivable

$2.1 m

Inventories

$1.2 m$1.9 m

Current Assets

$96.9 m$158.6 m

PP&E

$738 k$1 m

Total Assets

$97.7 m$162 m

Accounts Payable

$3.5 m$9.1 m

Current Liabilities

$8.4 m$25.6 m

Additional Paid-in Capital

$214.1 m$358.1 m

Retained Earnings

($129 m)($223.2 m)

Total Equity

$85.1 m$134.9 m

Financial Leverage

1.1 x1.2 x
FY, 2015FY, 2016

Net Income

($27.3 m)($94.2 m)

Depreciation and Amortization

$171 k$655 k

Accounts Receivable

($2.1 m)

Inventories

($659 k)($1.3 m)

Accounts Payable

$1.3 m$5.6 m

Cash From Operating Activities

($21.6 m)($75.1 m)

Purchases of PP&E

($362 k)($477 k)

Cash From Investing Activities

($362 k)($3 m)

Cash From Financing Activities

$116 m$135.6 m

Interest Paid

$353 k$284 k
Y, 2016

Financial Leverage

1.2 x

Collegium Pharmaceutical Market Value History

Collegium Pharmaceutical Company Life

You may also be interested in